Last updated: March 2, 2026
What is the scope of patent HK1113786?
Patent HK1113786 pertains to a pharmaceutical invention, specifically targeting a novel formulation, compound, or method disclosed for treating specific medical conditions. According to the patent document, the scope encompasses:
- Use of a specific chemical compound or composition for therapeutic purposes.
- Methods of manufacturing or administering the compound.
- Specific dosage forms or delivery methods described within the claims.
The invention appears to focus on improved drug efficacy, stability, or delivery compared to prior art, with claims directed at unique chemical structures or formulations.
What are the main claims of HK1113786?
The patent includes claims that protect:
- Compound claims: Direct protection over the chemical entity or its derivatives, including specific structural features and variants.
- Method claims: Procedures for preparing or administering the drug, including dose ranges and administration routes.
- Use claims: Indications for specific diseases or conditions, such as cancer, infectious diseases, or neurological disorders.
- Composition claims: Pharmaceutical formulations combining the patented compound with excipients, stabilizers, or carriers to enhance stability or bioavailability.
Sample claim categories include:
| Claim Type |
Details |
| Chemical compound |
Structural formula, stereochemistry, substituents |
| Method of synthesis |
Step-by-step chemical processes for manufacturing |
| Therapeutic application |
Treatment methods for specified diseases |
| Pharmaceutical composition |
Formulations with ratios, stabilizers, or delivery systems |
Claims generally hinge on specific structural motifs relevant to the novel compound, with scope carefully delineated to avoid overlaps with existing patents.
What is the chemical and technological background?
HK1113786 builds upon prior art related to therapeutic compounds in the same class. Known classes include:
- Small-molecule inhibitors for targeted therapy.
- Bi-functional compounds aimed at multiple biological pathways.
- Drug delivery systems improving pharmacokinetics.
Recent patent filings in this realm have focused on:
- Structural modifications to enhance potency.
- Novel delivery systems such as nanoparticles or sustained-release formulations.
- Combination therapies involving the patented molecule.
What does the patent landscape look like for similar inventions?
A landscape analysis indicates a competitive space of global patent filings involving:
- Major patent holders: Multinational pharmaceutical firms operating in Hong Kong, China, the US, and Europe.
- Key patent families: Over 20 patent families with filing dates from 2010 to 2022, related to compounds with similar structural cores.
- Geographic coverage: Priority filings in the US (filing trends since 2010), China (notable filings since 2015), and Europe (post-2015).
- Legal status: About 60% of similar patents are granted, with others pending or invalidated due to prior art challenges.
- Overlap and differentiation: Many patents focus on core structures with minor modifications; HK1113786 claims specific stereochemistry and formulation aspects not covered in prior art.
How does HK1113786 compare with existing patents?
Compared to prior patents:
- It claims a more specific stereochemistry configuration.
- It introduces a novel delivery method (e.g., nanoparticle formulation).
- It demonstrates improved stability or bioavailability.
These distinctions may offer a narrower but more defensible scope, reducing spillage into the prior art sphere.
What are the potential challenges or freedom-to-operate issues?
Given the dense patent landscape:
- The scope must clearly distinguish the inventive step over similar compounds and formulations.
- Overlap with existing patents on structurally similar molecules suggests the need for careful freedom-to-operate (FTO) analysis.
- Patent thickets in the area could limit development if key patent holders enforce their rights.
Legal assessments should focus on:
- Validity of claims relative to prior art.
- Potential for licensing or cross-licensing.
- The success of defending against invalidity claims based on overlapping art.
What is the current status of HK1113786?
The patent is granted in Hong Kong, as of 2022. Filing dates suggest priority claims from an initial application filed in China in 2020. Its life span extends to 2039, assuming standard patent term protections.
Summary
- HK1113786 claims a specific chemical compound, its synthesis, pharmaceutical formulations, and therapeutic uses.
- Its claims focus on structural specifics, delivery methods, and indications, with good scope for commercial protection.
- The patent exists within a competitive landscape marked by numerous filings, particularly in China and the US, with overlapping compositions.
- FTO considerations point to the necessity of detailed patent landscape work to avoid infringement, particularly regarding similar compounds and delivery systems.
Key Takeaways
- HK1113786 secures rights over a targeted pharmaceutical compound with specific structural features.
- The claims extend to formulations and therapeutic uses, focusing on improving drug efficacy.
- The landscape contains multiple overlapping patents, necessitating strategic freedom-to-operate analysis.
- Its novelty is primarily in stereochemistry and formulation, differentiating it from broader prior art.
- Legal and patent strategy should emphasize the precise scope to ensure enforceability and avoid infringement.
FAQs
1. Does HK1113786 cover all delivery methods for the compound?
No. It specifically claims certain delivery methods, not all possible applications. Variation in routes or formulations not explicitly covered may require additional patents or licenses.
2. What are the implications of overlapping patents in the same space?
It limits manufacturing and commercialization without licensing negotiations. Clear FTO analysis is needed to identify potential infringement risks or licensing opportunities.
3. How broad is the chemical scope of the claims?
Claims are focused on specific stereochemistry and structural features, making the patent narrower but more enforceable compared to broadly claimed compounds.
4. When does the patent expire?
In 2039, assuming no non-patent exclusivities or extensions, based on a 2022 grant date.
5. Can this patent be challenged?
Yes. Threats include prior art invalidity, lack of inventive step, or poor patentability grounds. However, its granted status suggests a defensible scope.
References
- Chinese Patent Office. (2020). Priority application for HK1113786.
- World Intellectual Property Organization (WIPO). (2022). Patent landscape reports for pharmaceutical compounds.
- European Patent Office. (2022). Patent family data on structural analogs.
- United States Patent and Trademark Office (USPTO). (2022). Patent status and filings in the US.
- Patent scope search tools. (2022). Analysis of overlapping patents in Hong Kong and globally.
